Cardiovascular
Idiopathic Pulmonary Arterial Hypertension
9
Pipeline Programs↗
0
Active Trials↗
8
Companies Involved↗
Idiopathic Pulmonary Arterial Hypertension is an early-stage landscape with 9 programs across 8 companies. The most active players are Teva, Bayer, Sanofi. 4 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 11
Phase 24
Phase 3
No programs
Analysis
Trial Status
5
clinical trials
Completed3 · 60%
Withdrawn1 · 20%
Terminated1 · 20%
Clinical Trials
Trial Activity
A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension
Completed·—·Phase 2·NCT00105209·20 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)